Tolerability and side-effects of bis- (hydroxy-2-ethylthio) -1,10-decane (BS 530) as compared with clofibrate in the therapy of hyperlipemia
Colombo, L.; Monarca, A.; Goldberg, D.; Zanetta, R.
La Clinica Terapeutica 91(2): 155-171
1979
ISSN/ISBN: 0009-9074 PMID: 540479 Document Number: 139641
Document emailed within 1 workday
Related Documents
Keller, C.; Wolfram, G.; Zöllner, N. 1976: Treatment of hyperlipemia and hyperuricemia with 2-acetamidoethyl-(4-chlorophenyl)-(3-trifluoromethylphenoxy)-acetate (halofenate), a derivative of clofibrate Arzneimittel-Forschung 26(12): 2221-2224Romman, A.; Salama-Hanna, J.; Dwivedi, S. 2018: Mexiletine Usage in a Chronic Pain Clinic: Indications, Tolerability, and Side Effects Pain Physician 21(5): E573-E579
Giorgetti, P.L.; Marenghi, M.C.; Bianciardi, P. 1997: Heparan sulfate in the therapy of postphlebitic syndrome. Evaluation of the efficacy and tolerability as compared to mesoglycan Minerva Cardioangiologica 45(6): 279-284
Mertz, D.P. 1980: Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate Fortschritte der Medizin 98(45): 1761-1766
De Gennes, J.L.; Dairou, F.; Surbled-Delas, B. 1978: Demonstration of the role of cholelithiasis in the onset of acute pancreatitis occurring during clofibrate (or its analog) treatment of atherogenic hyperlipemia Annales de Medecine Interne 129(6-7): 435-439
Contreras, J.L.; Eckhoff, D.E.; Cartner, S.; Frenette, L.; Thomas, F.T.; Robbin, M.L.; Neville, D.M.; Thomas, J.M. 1999: Tolerability and side effects of anti-CD3-immunotoxin in preclinical testing in kidney and pancreatic islet transplant recipients Transplantation 68(2): 215-219
Lutsky, B.N.; Millonig, R.C.; Wojnar, R.J.; Free, C.A.; Devlin, R.G.; Varma, R.K.; Karanewsky, D.S. 1986: Androstene-17-thioketals. 2nd communication: pharmacological profiles of tipredane and (11 beta, 17 alpha)-17-(ethylthio)-9 alpha-fluoro-17-[2-(fluoroethyl)thio]-11 beta-hydroxy-androsta-1,4-dien-3-one, structurally novel 20-thiasteroids possessing potent and selective topical antiinflammatory activity Arzneimittel-Forschung 36(12): 1787-1795
Reginster, J.Y.; Franchimont, P. 1985: Side effects of synthetic salmon calcitonin given by intranasal spray compared with intramuscular injection Clinical and Experimental Rheumatology 3(2): 155-157
Nye, E.R.; Sutherland, W.H.; Temple, W.a. 1980: The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate New Zealand Medical Journal 92(671): 345-349
Stevens, T.J.; Stafford, W.W.; Day, C.E.; Block, E.M. 1983: Comparison of clofibrate and ethyl-5-(p-chlorophenoxy)-3-hydroxy-3-methylpentanoate induced changes in serum lipoprotein cholesterol and hepatic peroxisome proliferation in the normal rat Artery 12(2): 81-94
Schmähl, D. 1971: Side-effects of cytostatic therapy with special reference to potential carcinogenic effects Der Internist 12: Suppl. 1: 115-9
Farkas, G.; Dégi, R.; Vörös, P. 1995: Long-term effects of fetal islet transplantation on complication of diabetes, as compared with effects of intensive insulin therapy Transplantation Proceedings 27(6): 3145
Dölle, W.; Daiss, W. 1988: Therapy of chronic inflammatory bowel diseases. Clinical aspects and therapy of drug-induced side effects Verhandlungen der Deutschen Gesellschaft für Innere Medizin 94: 184-191
Pander Maat, H.; Klaassen, R. 1996: The effect of the wording of information about side effects on patients' interpretation of reported side effects Nederlands Tijdschrift Voor Geneeskunde 140(8): 424-427
Britton, S. 2013: Vaccines must have a minimal amount of side effects. Serious side effects threatens public trust Lakartidningen 110(16): 816
Dooley, K.L.; Beland, F.A.; Bucci, T.J.; Kadlubar, F.F. 1984: Local carcinogenicity, rates of absorption, extent and persistence of macromolecular binding, and acute histopathological effects of N-hydroxy-1-naphthylamine and N-hydroxy-2-naphthylamine Cancer Research 44(3): 1172-1177
Hynes, M.; Bournes, L.; Brich, A.; Cupernall, G.; Hanzelin, J.; Ramming, K.; Pitler, L.R. 1990: Managing side effects associated with IL-2 therapy Oncology Nursing Forum 17(6): 963-964
Schreiber, G. 1975: Side-effects of chloramphenicol therapy Zeitschrift für Arztliche Fortbildung 69(12): 631-636
Ciocca, M.; Daruich, J.; Fernández, N. 2005: Side effects of therapy and management Acta Gastroenterologica Latinoamericana 35(Suppl 1): S59-S62
Vcev, A. 2009: Management of side effects during antiviral therapy Acta Medica Croatica: Casopis Hravatske Akademije Medicinskih Znanosti 63(5): 463-467